TY - JOUR
T1 - Sublingual misoprostol
T2 - A better choice for cervical priming before manual vacuum aspiration
AU - Shetty, J.
AU - Chawla, R.
AU - Pandey, D.
AU - Kamath, A.
AU - Guddattu, V.
PY - 2010/8/1
Y1 - 2010/8/1
N2 - Background: Misoprostol is effective for cervical priming before manual vacuum aspiration (MVA). Aim of study was to determine whether sublingual misoprostol with a shorter interval of 2 hours before MVA would be as effective as its standard vaginal administration. Study Design: This randomized control trial included 82 women randomly assigned to receive 400 mcg of misoprostol, either sublingually or vaginally. MVA was performed 2 hours and 3 hours after in sublingual and vaginal group, respectively. Results: Cervical dilatation of 8 mm was achieved within 2 hours in sublingual group. Mean time taken for procedure (14.4 5.3: sublingual group and 16.2 5.7: vaginal group), and blood loss was comparable (12.2 9.7 ml in sublingual group and 13.7 8.5 ml in vaginal group). Conclusion: 2 hour of cervical priming with 400 mcg of sublingual misoprostol before MVA was as good as 3 hours with vaginal administration of the same dose.
AB - Background: Misoprostol is effective for cervical priming before manual vacuum aspiration (MVA). Aim of study was to determine whether sublingual misoprostol with a shorter interval of 2 hours before MVA would be as effective as its standard vaginal administration. Study Design: This randomized control trial included 82 women randomly assigned to receive 400 mcg of misoprostol, either sublingually or vaginally. MVA was performed 2 hours and 3 hours after in sublingual and vaginal group, respectively. Results: Cervical dilatation of 8 mm was achieved within 2 hours in sublingual group. Mean time taken for procedure (14.4 5.3: sublingual group and 16.2 5.7: vaginal group), and blood loss was comparable (12.2 9.7 ml in sublingual group and 13.7 8.5 ml in vaginal group). Conclusion: 2 hour of cervical priming with 400 mcg of sublingual misoprostol before MVA was as good as 3 hours with vaginal administration of the same dose.
UR - http://www.scopus.com/inward/record.url?scp=84866150417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866150417&partnerID=8YFLogxK
U2 - 10.4103/0019-5359.100338
DO - 10.4103/0019-5359.100338
M3 - Article
C2 - 22945779
AN - SCOPUS:84866150417
SN - 0019-5359
VL - 64
SP - 356
EP - 362
JO - Indian Journal of Medical Sciences
JF - Indian Journal of Medical Sciences
IS - 8
ER -